More on ACXP

- Summary
- Chart
- Profile
- Historical

Data

- Earnings (+100.0% Growth)
- Ratings (10.0 Score)

Upcoming Events

- Earnings (3/18/26 *Est.)

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

Acurx Pharmaceuticals (NQ:ACXP)
Delayed: 1.35 -0.1 (6.9%)
Prev. Close $1.45  
Open$1.45 
52 Wk High$ 
52 Wk Low$ 
Day High$1.47 
Day Low$1.33 
P/E N/A  
EPS$ 
Volume64,043 

Friends, Peers and Foes (?): PETV, RDZN, LASE, SNYR, AERT (more...)

Feb 16, 2026 08:01 AM Acurx Pharmaceuticals to Discuss Full Year and Fourth Quarter 2025 Financial Results on March 13, 2026 Conference Call and Provide Business Update
Feb 12, 2026 06:06 AM Form EFFECT Acurx Pharmaceuticals,
Feb 11, 2026 04:22 PM Form 424B3 Acurx Pharmaceuticals,
Feb 2, 2026 04:48 PM Form S-1 Acurx Pharmaceuticals,
Feb 2, 2026 08:00 AM USPTO Grants Acurx Pharmaceuticals New Patent for DNA Polymerase IIIC Inhibitors
Jan 7, 2026 06:02 AM Form EFFECT Acurx Pharmaceuticals,
Dec 30, 2025 04:03 PM Acurx Pharmaceuticals (ACXP) files $50M mixed shelf
Dec 30, 2025 04:01 PM Form S-3/A Acurx Pharmaceuticals,
Nov 22, 2025 11:20 AM New to The Street Show #702 Airs Today on Bloomberg at 6:30 PM EST
Nov 18, 2025 08:00 AM Health~Holland Awards Another Innovative Research Grant for DNA Pol IIIC Inhibitors to Leiden University Medical Center and Acurx Pharmaceuticals
View All Articles

Entities mentioned with ACXP

View All Entities